Results 91 to 100 of about 1,218 (152)

Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review. [PDF]

Front Pharmacol
Yang Y, Wang K.
europepmc   +1 more source

Effect of Baseline Values of Renal Prognosis-related Factors on Their Changes after Initiating Tofogliflozin Treatment: A Retrospective Study in Japanese Patients with Type 2 Diabetes and Renal Impairment. [PDF]

JMA J
Matsumoto S, Ito H, Inoue H, I C, Miura S, Antoku S, Yamasaki T, Mori T, Togane M.   +8 more
europepmc   +1 more source

Synthetic Flozins in Cancer Prevention and Combination Strategies: Structural Insights and Therapeutic Potential. [PDF]

Molecules
Zieliński M, Michalak O, Ruszczak M, Cybulski M.   +3 more
europepmc   +1 more source

Effect of SGLT-2 inhibitors on liver fibrosis progression in patients with MASLD: an updated meta-analysis based on RCTs. [PDF]

Front Med (Lausanne)
Yang L, Ruan J, Fang Y, Xu A.
europepmc   +1 more source

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.

Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.
令和3年度 Recent studies have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors have a favorable effect on cardiovascular events in diabetic patients. However, the underlying mechanism associated with a favorable outcome has not been clearly identified. The purpose of this study was to investigate the effect of tofogliflozin, SGLT2 inhibitor, on
openaire  

Effects of 6-month administration of tofogliflozin on cardiac function in elderly patients with heart failure with preserved ejection fraction: A retrospective study of a patient cohort. [PDF]

Medicine (Baltimore)
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kuroki K, Haraguchi T, Yamada S, Sangen R, Kiyosawa J, Saito A, Iguchi M, Nakahashi T, Kasamaki Y, Fukuda A, Kanda T, Okuro M.   +15 more
europepmc   +1 more source

Effects of Switching From Another Sodium-Glucose Cotransporter 2 Inhibitor to Tofogliflozin on Nocturia in Patients With Type 2 Diabetes. [PDF]

Cureus
Inoue S, Yasuda H, Yoshida K, Mori K, Ogawa K, Yokotsuka Y, Okamoto H.   +6 more
europepmc   +1 more source

SGLT2 Inhibitors and the Risk of Infections in Type 2 Diabetes: Systematic Review and Meta-Analyses of Real-World Evidence. [PDF]

J Diabetes Res
Alfonso Arvez MJ, Tan GSQ, Leung MTY, Ademi Z, Bell JS.   +4 more
europepmc   +1 more source

SGLT2 Inhibitors as Systemic Metabolic Modulators: Linking Glucose Excretion to Liver Function Restoration. [PDF]

Endocrinol Metab (Seoul)
Noh SW, Ryu HS, Kim YH, Oh BC.
europepmc   +1 more source

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?

Archives of Medical Science – Atherosclerotic Diseases, 2018
openaire   +2 more sources